HETLIOZ (TASIMELTEON) CAPSULES
Live / Registered — Registered (as of 09 Aug 2022)
What this means for you
Registered since 09 Aug 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88819345
- Registration number
- 6815599
- Mark type
- Design + words
- Filed
- 03 Mar 2020
- Published for opposition
- 17 Aug 2021
- Registered
- 09 Aug 2022
- Attorney of record
- Jayme M. Torelli
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, containing tasimelteon, for use in the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations, containing tasimelteon, for use in the treatment of sleep disorders
Owner
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
Prior registrations
Prosecution history
- 09 Aug 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 09 Aug 2022 — REGISTERED-PRINCIPAL REGISTER
- 07 Jul 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 06 Jul 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 09 Jun 2022 — ASSIGNED TO EXAMINER
- 21 Apr 2022 — STATEMENT OF USE PROCESSING COMPLETE
- 11 Apr 2022 — USE AMENDMENT FILED
- 21 Apr 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 11 Apr 2022 — TEAS STATEMENT OF USE RECEIVED
- 12 Oct 2021 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Aug 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Aug 2021 — PUBLISHED FOR OPPOSITION
- 28 Jul 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Jul 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 03 Jul 2021 — TEAS/EMAIL CORRESPONDENCE ENTERED